共 264 条
[1]
Rawla P(2019)Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors Rev World J Oncol. 10 10-27
[2]
Sunkara T(2008)Pancreatic neuroendocrine tumours Eur J Surg Oncol. 34 324-332
[3]
Gaduputi V(2017)Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis J Cancer 8 3615-3622
[4]
O’Grady HL(2021)Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection HHS Public Access Gastroenterol. 160 1373-1383
[5]
Conlon KC(2010)Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer Surg. 8 239-246
[6]
Meng Q(1990)The clinical utility of the CA 19–9 tumor-associated antigen Am J Gastroenterol 85 350-355
[7]
Fahrmann JF(2007)Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer Eur J Surg Oncol. 33 266-270
[8]
Raptis DA(2021)Pancreatic Cancer: A Review JAMA 326 851-862
[9]
Fessas C(2023)‘Pancreatic Cancer: A Review of Current Treatment and Novel Therapies J Investig Surg Off J Acad Surg Res. 36 2129884-2406
[10]
Belasyse-Smith P(2018)FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer N Engl J Med. 379 2395-1585